DEALS: Genzyme, Isis ink $1.9B pact


Genzyme, Isis ink $1.9B pact


DEALS

WHO

WITH

WHAT

SCOOP

Genzyme

Isis Pharmaceuticals

$1.9B deal

The deal is for Isis' promising cardiovascular drug mipomersen, its flagship product. Genzyme is paying $175 million in an upfront fee and will buy five percent of the company.

Merck

Addex Pharmaceuticals

$702M licensing deal

Merck is paying $22 million up front and up to $455 million more for regulatory, sales and development milestones for ADX63365, a schizophrenia drug candidate.

Pfizer

Scil Technology

$250M licensing deal

Pfizer gains worldwide to an experimental osteoarthritis therapy under development at Germany's Scil Technology. Scil has been developing a cartilage specific growth factor--CD-RAP--to regenerate tissue in degenerative joints.

WuXi PharmaTech

Apptec

$151M buyout

WuXi gains Apptec's biologics capabilities along with U.S. market presence.

Invitrogen

CellzDirect

$57M buyout

CellzDirect provides R&D operations hepatocyte-based cell products and other services used to test new drugs.

Pfizer

Taisho

$22M deal

Japan's Taisho has granted all commercial rights to its preclinical schizophrenia drug outside of Japan to Pfizer for $22 million up front.

Ipsen

Salk Institute

$10M

Over the next three to five years, Ipsen will pay Salk $10 million dollars to research three disease areas: cancer biology, degenerative diseases and maladies associated with metabolic syndrome.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.